Busulfan is an alkylating agent currently used in the myeloablative conditioning regimen before stem cell transplantation. Its mechanism of action is not fully understood, nor the reason for its narrow therapeutic window. We studied the pharmacodynamics of busulfan in an in vitro cell line model, allowing us to evaluate the effects of various doses and exposure times on clonogeneic capacity, proliferation and apoptosis. Cells were incubated with busulfan in concentrations ranging from 10 to 100 g/ml for 2, 4 or 8 h, then washed and cultured in busulfanfree medium for 72 h. Area under the concentration-time curve (AUC) was estimated by using the trapezoidal rule from different concentrations and times of incubation. In all assays busulfan affected the cells in an AUC-dependent manner. Induced changes in the biological parameters studied appeared at different time points after exposure to busulfan stopped. Thus, the decrease in proliferation and clonogenic capacity preceded cell cycle arrest in G2 phase and development of apoptosis, implying that apoptosis is a secondary event to interruption of vital metabolic processes. Biochemically, apoptotic changes were typical for chemotherapy-induced apoptosis with caspase activation, cleavage of Bcl-2 and PARP proteins, while cleavage of actin was not observed. Cells were rescued from apoptosis with a general caspase inhibitor ZVAD-fmk, but not with granulocyte colony-stimulating factor (G-CSF). Our results add new information about busulfan pharmacodynamics and mechanisms underlying the cytotoxic effect of the drug. Leukemia (2001) 15, 1240-1247.
Introduction
Busulfan is a bifunctional alkylating agent and has been used in the treatment of chronic myeloid leukemia since the 1950s. Currently, busulfan is part of the myeloablative-conditioning regimen before stem cell transplantation. Pharmacokinetic studies have verified great inter-patient variations due to age, circadian rhythmicity, underlying diseases and drug-drug interaction. [1] [2] [3] Busulfan bioavailability varies six-fold in children and two-fold in adults. 4 Acute toxicity of busulfan, such as CNS toxicity and veno-occlusive disease (VOD), correlates with a high systemic exposure expressed as area under the plasma concentration-time curve (AUC). 5, 6 Busulfan has been shown to affect primary hematopoietic cells and hematopoietic cell lines in vitro. Proliferation of HL-60 cells and the surviving fraction of clonogenic cells in HL-60, K562 and L1210 cell lines were decreased in a concentration-dependent manner. 7, 8 A cytotoxic effect of busulfan was also found in other cell types. One murine mammary tumor cell line, two human bladder tumor cell lines and two human colon carcinoma cell lines were found to be sensitive in a concentration-dependent manner. 8, 9 Busulfan-induced cell death has been studied in vivo and in vitro with conflicting results. Cells in crypts of small intestine of mice were shown to undergo apoptosis as a response to busulfan treatment in vivo. 10 On the other hand, no increase in apoptosis was detected in bone marrow smears and trephine biopsies from patients treated with busulfan for CML. 11 However, a recent study showed that busulfan induced apoptosis in malignant pre-B cell or B cell lines in vitro. 12 Apoptosis is a type of cell death encoded in cell genome. The mechanism of programmed cell death is conserved through species from worms to mammals, and shows, irrespective of the organism, several common steps. Apoptotic morphology is characterized by cell shrinkage, membrane blebbing, condensation of cytoplasm and DNA and formation of apoptotic bodies. Biochemical changes are characterized by activation of caspases, cleavage of substrates participating in cellular homeostasis or metabolism, and finally activation of endonucleases responsible for fragmentation of DNA. 13 Apoptosis is a prerequisite for the homeostasis of a multicellular organism and, as such, has to be in balance with cellular proliferation. Dysbalance may lead to diseases characterized by either too little or too much apoptosis.
14 Apoptosis may be induced in both primary cells and cell lines by physical or chemical stimuli, such as drugs or toxic compounds, hormones, or by cytokine withdrawal. [15] [16] [17] P39 is a myeloid cell line established from a patient suffering from acute leukemia following a myelodysplastic syndrome, and is easily induced to differentiation and/or apoptosis with different agents. 18, 19 We have previously used this cell line as a model for studies of apoptosis induced with the cytostatic agent etoposide, and a differentiating agent, alltrans retinoic acid (ATRA). We found two pathways of apoptosis, both mediated through caspase activation, but different from each other in terms of kinetics of apoptotic changes, presence or absence of maturation, the effect of granulocyte colony-stimulating factor (G-CSF) rescue, and cleavage of actin and Bcl-2. 20 The aim of the present investigation was to study in vitro pharmacodynamic effects of busulfan, ie the relation between the exposure to busulfan and its cytotoxic effect, in the myeloid P39 cell line model. We also addressed questions about busulfan-induced apoptosis and its underlying mechanism. We used AUC as a measurement of exposure to busulfan in vitro and found in all assays performed that the effect of busulfan was AUC dependent. In addition, our study adds new information to the understanding of the mechanism of busulfan-induced cytotoxicity.
Materials and methods

Chemicals
The following materials were used throughout the experiments: RPMI 1640 medium with Glutamax-I and 25 mM Hepes, phosphate-buffered saline PBS Dulbecco's, fetal bovine serum and penicillin/streptomycin (Life Technologies, Paisley, UK); busulfan (Welcome Foundation, Beckenham, UK); etoposide (Bristol-Myers Squibb, Bromma, Sweden); granulocyte colony-stimulating factor (F Hoffmann-La Roche, Basel, Switzerland); 
Cell cultures
The P39 cell line was kindly provided by Prof Y Yoshida (Center for South East Asian Studies, Kyoto University, Kyoto, Japan). Cells were grown in RPMI 1640 medium supplemented with 10% heat inactivated fetal bovine serum (FBS), penicillin (25 IU/ml) and streptomycin (25 g/ml) at 37°C in a humidified 5% CO 2 atmosphere. Cells were seeded at a concentration of 0.20 × 10 6 cells/ml. All experiments were done in exponentially growing cells. Cells were incubated with busulfan (final concentration of 10, 20, 40, 60, 80 or 100 g/ml) for 2, 4 or 8 h. Then, cells were washed and recultured in busulfan-free medium until 72 h. Cells incubated in medium supplemented with 10% FBS or in medium with 10% FBS and 0.5% DMSO served as controls in all experiments. The cells treated with etoposide with a final concentration of 6 g/ml served as a positive control for apoptosis. G-CSF concentration of 100 ng/ml was added to the cultures simultaneously with busulfan. ZVAD-fmk of 50 M was added to cultures 1 h before busulfan, at the start of busulfan-free reculturing, and at 24 and 48 h in busulfan-free cultures.
Drug dilution
Busulfan was diluted in sterile DMSO and then in medium before addition to cell suspension. The final concentration of DMSO was 0.5%.
Proliferation
Aliquots of 0.2 ml of cell suspension were incubated in triplicate on 96-well microplates with 1 Ci (20 l of 50 Ci/ml) 3 H-labelled thymidine for 4 h at 37°C. Incubation was initiated before incubation with busulfan, after incubation with busulfan and after 24, 48 and 72 h in busulfan-free cultures. The cells were harvested on a filter with a Cell Harvester (Skatron, Norway). The activity was measured in scintillation fluid (OptiScint Hisafe, Amersham Pharmacia Biotech) using a liquid scintillation counter (WALLAC, EG&G Comp, Turku, Finland). Proliferation index (PrI) expresses the number of population doublings in the drug-treated cultures compared to control cultures and was counted according to the formula (LogN 72 /N 24 ) Bu /(LogN 72 /N 24 ) DMSO , where N is the number of cells at the appropriate time point. 21 
Cell number, viability and differentiation
Cell number and viability were determined with trypan blue exclusion. Differentiation was determined using nitrobluetetrazolium test (NBT) after stimulation with phorbol-myristate-acetate (PMA). 22 Cytospin preparations were air dried, fixed in methanol and counter-stained with May-Grü nwaldGiemsa. The percentage of cells containing dark blue formazan deposits was counted in a total of 400 cells.
Leukemia
Cell cycle analysis
The cells were washed once in PBS, fixed in 70% ethanol in PBS and stored at −20°C. For analysis, the cells were washed in cold PBS and stained in hypotonic PI (propidium iodide) solution (20 g/ml) containing DNase-free RNase (100 g/ml). The acquirement and analysis were done on a FACScan flow cytometer using CELL Quest software (Becton Dickinson, San Jose, CA, USA).
Clonogenic assay
The cell suspension was diluted with medium to cell density of 5000 cells/ml. Ten volumes of methylcellulose medium were mixed with one volume of cell suspension. Five hundred cells in 1.1 ml of methylcellulose were plated in triplicate in 35 mm Petri dishes and incubated at 37°C in a humidified 5% CO 2 atmosphere. Colonies (50 or more cells) were counted on day 7.
Assessment of apoptosis
Apoptotic cells were assessed in May-Grü nwald-Giemsa staining on cytospun slides. The cells with morphological features, such as fragmented nuclei and condensed chromatin, were counted. Apoptosis was estimated as a percentage of a minimum of 400 cells counted per slide. DNA fragmentation assay as described previously 23 was used and DNA from two million cells were loaded per well to confirm the apoptotic origin of morphological changes.
Protein quantification
Total cellular protein was quantified with a colorimetric assay (Bio-Rad protein assay, Bio-Rad, Hercules, CA, USA) based on the Bradford dye-binding method according to the recommendations of the manufacturer.
SDS-PAGE and Western blot
Cells were lysed for 30 min on ice in lysis buffer (50 mM Tris pH 7.4, 150 mM NaCl, 25 mM EDTA, 0.01% sodium azide, 1 mM sodium fluoride, 0.5 mM PMSF, leupeptin 10 g/ml, aprotinin 10 g/ml, pepstatin 2 g/ml, 1 mM DTT, 1 mM sodium orthovanadate, 1% Igepal) and stored at −70°C. Cell lysate was thawed and mixed with double concentrated Laemmli buffer. Thirty micrograms of protein per well were loaded. Proteins were separated by SDS-PAGE on 7.5 or 12% Tris-HCl Ready Gel (Bio-Rad) and then transferred to a PVDF membrane. The PVDF membrane was blocked in 5% nonfatty dry milk solution and than incubated with antibodies against Bcl-2 (1:100; DAKO, Glostrup, Denmark), actin (1:1000; Sigma), PARP (1:100; Oncogene Research Products, Boston, MA, USA) or caspase-3 (1:1000; PharMingen International, San Diego, CA, USA). After washing, the membrane was incubated with a peroxidase-conjugated secondary antibody (1:2500; Amersham Pharmacia Biotech). The enhanced chemiluminiscence (ECL+Plus; Amersham Pharmacia Biotech) was used for visualization.
Leukemia
Pharmacokinetics and statistics
The half-life of busulfan in RPMI at 37°C was determined to be 16 h and thus k = 0.043. Busulfan concentration was assessed using gas chromatography with electron capture detection as described previously. 24 The concentration of busulfan at the end of incubation was calculated as C = C 0 .e −kt . 25 AUC was calculated according to the trapezoidal rule. 26 Data are expressed as mean ± s.d. of three separate experiments.
Results
Effects on proliferation and clonogenic capacity are AUC dependent
Busulfan affected the cells in an AUC-dependent manner. Proliferation measured with 3 H-thymidine incorporation expressed as percent of control and PrI decreased with increasing AUC (Figure 1a and b) . Decrease in thymidine incorporation was more pronounced during the period when the cells were recultured in busulfan-free medium for 24, 48 or 72 h. Co-incubation with G-CSF or ZVAD-fmk did not influence the decrease in proliferation (data not shown).
The effect of busulfan on clonogenic capacity was AUC dependent and appeared immediately after the end of incubation. Cells exposed to busulfan of AUC less then 160 g·h/ml fully or partially recovered during the culture period in busulfan-free medium, while the recovery of the cells exposed to AUC equal or greater than 160 g·h/ml was not significant (Figure 1c) . Figure 1d illustrates how similar AUCs obtained by combinations of concentrations and times of incubation gave similar effects on the clonogenic growth of P39 cells.
Busulfan-induced apoptosis is AUC dependent and delayed
Busulfan-induced apoptosis was detected by morphology and confirmed with DNA ladder (Figure 2a ). Busulfan induced apoptosis in a concentration-and timedependent manner. No signs of apoptosis were observed during incubation with busulfan. In spite of the effects on proliferation, apoptosis was delayed and appeared within 3 days in the busulfan-free cultures. Apoptosis induced with busulfan for 4 h of incubation is shown in Figure 2b . Similar patterns were observed after 2 and 8 h of incubation with busulfan, but the levels of apoptosis reached in busulfan-free medium were different. The percentage of apoptosis induced with a concentration of busulfan of 100 g/ml for 2 h was 8, 16 and 45% at 24, 48 and 72 h, respectively. The same concentration of busulfan for 8 h induced apoptotic morphology in 47, 80 and 94% of cells at comparable time points. When exposure to busulfan was expressed as AUC, a linear relation between the AUC and apoptosis was found at 48 and 72 h of busulfanLeukemia free cultures (Figure 2c ). No signs of preceding maturation were detected with nitro-blue tetrazolium test. ZVAD-fmk decreased apoptosis by approximately 50%, while cells could not be rescued from apoptosis with G-CSF (Figure 2d ).
Apoptosis is preceded by cell cycle arrest in G2 phase
About 20% of the cells were in G2 phase of cell cycle during exponential growth. Busulfan induced G2 arrest in a concentration-and time-dependent manner. The changes in cell cycle distribution were observed after incubation with busulfan at a concentration of 20 g/ml or more for 8 h. Twentyfour hours after incubation with busulfan, cell cycle was dis-Leukemia turbed in all concentration and time combinations tested. When the cells were grown further in busulfan-free medium, either cell cycling was restored or the cells underwent apoptosis. The cell cycle was restored at the lowest concentrations for the shortest incubation time (10 and 20 g/ml for 2 h). Cells exposed to higher concentrations of busulfan or for longer incubation times manifested irreversible disturbance of the cell cycle (Figure 3) . Cell cycle arrest in G2 phase of cell cycle detected by FACS was paralleled by an increase in cell size detected in Giemsa staining and preceded the development of apoptotic morphology.
Proteolytic events involved in busulfan-induced apoptosis
A Bcl-2 fragment of 23 kDa and a PARP fragment of 85 kDa were detected 24 h after exposure to busulfan. The active subunit p17 of caspase-3 was detected at 48 h after incubation with busulfan. Actin cleavage was not found (Figure 4a ). Cleavage of Bcl-2 was blocked by ZVAD-fmk at 24 and 48 h, while cleavage of caspase-3 was not blocked. An additional band of 19 kDa was detected in ZVAD-fmk-treated cells (Figure 4b ).
Discussion
Busulfan is an alkylating agent with relative selectivity to hematopoietic stem cells and is widely used in the myeloablative conditioning regimen before stem cell transplantation. Busul-
Figure 3
Representative experiment showing cell cycle profiles in the P39 cells treated with busulfan. The P39 cells were incubated with busulfan, DMSO or medium for 2 h, washed and than recultured in busulfan-free medium for 24, 48 or 72 h. The cells were fixed in 70% ethanol and stained with PI for DNA content. DNA profiles were acquired with flow cytometry and G2 phase was estimated by 'halving' the G-peak method. The percentage of the cells in G2 phase of the cell cycle is shown in the histogram. fan toxicity in patients has been shown to be AUC dependent, and its cytotoxic effect in vitro has been suggested to be concentration and time dependent. [5] [6] [7] [8] [9] However, concentrations and incubation times differ considerably between published in vitro studies, as do the methods used to assess the cytotoxic effect of busulfan. This has made it difficult to fully assess the therapeutic potential of the drug. Recently, it has been shown that a conditioning regimen with so-called targeted busulfan plasma concentrations may improve outcome after stem cell transplantation, thus motivating further attempts to characterize the therapeutic window of busulfan.
The aim of the present study was to assess the pharmacodynamic effects of busulfan on a myeloid cell line, P39, and to study the mechanisms behind busulfan-induced cytotoxicity and apoptosis.
Results of in vitro experiments are often presented as concentration and time dependent. We believe, that these parameters are not independent, and thus, AUC is a more relevant expression of exposure to drug. We have selected AUCs ranging between 0 and 700 g·h/ml, which is in good agreement with total AUCs during the conditioning regimen before stem cell transplantation. 2, 3, 5, 27 Busulfan pharmacodynamics in vitro showed a linear relation between the AUC and busulfan effects in most parameters studied. Moreover, different biological events, such as reduction of proliferation, blocking of cell cycle, and apoptosis were time-related to each other in a clear and repeatable manner. Some effects already occurred after even a short incubation with busulfan, while others were delayed from hours to days. Proliferation assessed with incorporation of 3 H-thymidine decreased with increasing AUC according to
Figure 4
Proteolytic events during busulfan-induced apoptosis. (a) P39 cells were incubated with busulfan in concentrations of 40 or 80 g/ml for 4 h, then washed and recultured in busulfan-free medium for 48 h. DMSO of 0.5% served as a control culture, etoposide of 6 g/ml for 8 h served as a positive control for apoptotic proteolysis. Bcl-2, PARP and caspase-3 cleavage products were detected, while actin was not cleaved. (b) P39 cells were preincubated with 50 M ZVAD-fmk, incubated with busulfan in concentrations of 20, 40 or 80 g/ml for 4 h, then washed and recultured in busulfan-free medium for 48 hours. Medium and DMSO of 0.5% served as a control culture, etoposide of 6 g/ml for 8 h served as a positive control for apoptotic proteolysis. Bcl-2 cleavage was blocked with ZVAD-fmk at 24 and 48 h, while cleavage of caspase-3 was not blocked and additional band appeared at 48 hours after busulfan exposure stopped. a linear scale, also in the phase when cells were cultured in busulfan-free medium. This method cannot differentiate between proliferation and DNA repair, which means that it may overestimate proliferation. A decrease in proliferation was also observed in HL-60 cells treated with busulfan for 1 h. 21 When AUCs were calculated from concentrations and exposure time, PrI showed a similar decrease with 50% inhibition at about 100 g·h/ml. These results are in contrast to a radiometric assay in HL-60 cells, in which no effect of busulfan concentrations ranging from 8.6 to 85.5 g/ml continuous exposure for 6 days was found. 28 The clonogenic capacity of the P39 cells decreased immediately after the exposure to busulfan. The effect was AUC dependent, and clonogenic capacity was abolished with AUC above 160 g·h/ml. However, cells incubated at lower AUCs partially recovered in busulfan-free cultures. This recovery was also qualitative, ie the size of colonies at the day of assessment was comparable with the control cultures. With increasing AUC, the colonies diminished in size, and there was no cluster formation. Our results are in agreement with others showing suppression of clonogenic formation in K562 and HL-60 cell lines after busulfan treatment in vitro. 8 The AUCs producing a surviving fraction of about 50% were estimated to be 130 g·h/ml in K562 and 25 g·h/ml in HL-60 cells. These experiments, however, did not follow the recovery of cells in busulfan-free cultures. Primary cells from CML Leukemia patients showed a similar sensitivity to busulfan in vitro as the P39 cells. 29 No effect was observed for concentrations less than 5 g/ml for 4 h (calculated AUC 18 g·h/ml), while colony and cluster formation was completely inhibited by concentrations greater than 20 g/ml for 4 h (calculated AUC 74 g·h/ml).
Thus, the effect of busulfan in vitro is AUC dependent within the measured range, and comparable with what has been observed in primary cell cultures. A similar pattern of the effects of busulfan was observed in the K562 cell line in vitro (data not shown). It is therefore likely that the P39 cell line may serve as a good system for studying the effects of busulfan in vitro.
Busulfan induced apoptosis with typical morphology and DNA ladder formation in the P39 cell line. As in the proliferation and clonogenic assays, the pharmacodynamic pattern was linear, but clear apoptotic morphology appeared after a time delay of some days (Figure 2b and c) . No signs of preceding maturation were found either in morphology or NBT test. This opposes the finding in HL-60 cells, where 4 days exposure to busulfan was accompanied by NBT positivity. 30 The proteolytic events in busulfan-induced apoptosis showed a similar pattern to etoposide-induced apoptosis. 20 Bcl-2, PARP and caspase-3 were cleaved, while actin remained intact. The difference was that these events were clearly delayed compared to those observed in etoposideinduced apoptosis, which appeared within a few hours. A general caspase inhibitor, ZVAD-fmk, blocked the development of apoptotic morphology but did not improve proliferation. This means that caspase inhibition postponed the execution of apoptosis but did not restore cell function. Interestingly, ZVAD-fmk fully inhibited the Bcl-2 cleavage, but failed to block the formation of the p17 subunit of caspase-3. The busulfan-induced changes in the P39 cells could not be reversed by the addition of G-CSF, which is similar to reported previously with etoposide. 20 Busulfan-treated cells were arrested at the G2 cell cycle phase. After incubation was completed, while being cultured in busulfan-free medium, the further fate of P39 cells depended on the total exposure to busulfan, as measured by AUC. The lowest exposure induced a transient G2 arrest after which cell cycle was restored. The higher exposures (more than AUC 40 g·h/ml) induced irreversible changes that progressed in busulfan-free cultures. Despite the decrease in DNA content in apoptotic cells, observed as a shift to the left on the PI axis in histograms, the percentage of cells undergoing apoptosis could not be directly estimated with this method since their DNA content overlapped the S-phase-G1 phase areas of the histogram. Our results are in agreement with other studies. The cell cycle arrest in G2 phase was observed in several human cancer cell lines cultured in busulfan for 72 h. 9 However, restoration of cell cycle after exposure to busulfan was not studied. In Chinese hamster cells incubated with busulfan cell cycle arrest in G2 phase was only time-limited and the cells subsequently returned to normal cell cycle distribution. 31 Comparing the kinetics of cell cycle arrest detected with FACS and kinetics of morphological apoptotic changes, we showed that G2 arrest preceded development of apoptotic morphology. Thus, busulfan probably does not induce apoptosis by a direct triggering mechanism. It is possible that apoptosis is a secondary event following the block or inhibition of important cellular functions, which has also been observed in other forms of chemotherapy-induced apoptosis. 32 Our results may serve as a basis for future studies.
It is difficult to compare results from in vitro and in vivo studies or to make a clinical interpretation from in vitro data. However, pharmacodynamic studies in vivo are cumbersome. While the concentrations of the drug are usually studied in the plasma compartment, the distribution of the drug to tissues and cells is different and also reflects the chemical property (lipophility) of the drug and body composition of the patient. Thus concentration of the drug around the cells of interest can significantly differ from concentrations in plasma. Ethical and practical reasons limit the number of samples that can be used for AUC estimation in vivo and thus increase the variation in exposure estimates. On the other hand, pharmacodynamic studies in vitro are limited to drugs, which do not need to be activated in the body. In addition, the effect of potential still unknown metabolites is abandoned in vitro, as well as the network of agonistic and antagonistic factors. Being aware of the above-mentioned problems, we believe that in vitro studies may give an insight into the pharmacodynamics of drugs as well as an increased knowledge about the cellular events underlying drug effects.
We showed that the pharmacodynamic effect of busulfan within the studied range is linear, and that the total exposure of busulfan is probably the main factor both for the myeloablative effect and the complications of conditioning regimen for stem cell transplantation. It is in agreement with clinical experience that conditioning-related complications are AUC related and also corresponds with clinical experience that different dosing schedules produce the same effect. 27, 33 Altogether, this supports the use of therapeutic drug monitoring and dose-adjustment during conditioning regimens. In vitro studies have shown that hepatocytes are much less sensitive to busulfan than hematopoietic cells. Thus, an intravenous administration of busulfan overcoming the first pass effect may decrease the exposure of hepatocytes to busulfan to subtoxic levels while still keeping the myeloablative effect. Another theoretical implication, ie the use of caspase inhibitor in the case of drug overdose, may on the other hand, be irrelevant. Despite the fact that the cells induced to apoptosis with busulfan were partially rescued by ZVAD-fmk, only morphological changes were inhibited and proliferation was not restored.
In conclusion, the effect of busulfan was linearly related to AUC in myeloid P39 cells. Functional changes such as a decrease in proliferation and colony formation and arrest of cell cycle in G2 phase preceded the development of apoptosis, which implies that apoptosis is only a secondary event due to interruption of vital metabolic processes which still remain to be characterized. However, the biochemical apoptotic changes observed in our study were typical for chemotherapy-induced apoptosis; they showed considerable kinetic differences compared to etoposide-induced apoptosis. Our results add new information about busulfan pharmacodynamics and the mechanisms underlying the cytotoxic effect of busulfan. Provided the strong relationship between effect and AUC is also present in primary human leukemic cells, our findings may lead to the development of a new concept of conditioning regimen for stem cell transplantation.
